Conclusion of a non-exclusive discount contract pursuant to Section 130a (8) SGB V for medicinal products with the active ingredient raltegravir (ATC code: J05AX08) within the period from October 1, 2020 to September 30, 2022 with the option of concluding the contract at any time during the term ("open house model ").
The contractual partners can be viewed at: https://www.aok-gesundheitpartner.de/nds/arzneimittel/rabatt/index_03504.html?bl=nds
Until the entry into force of exclusive contracts after a public invitation to tender according to the regulations of Part 4 of the GWB, the AOK - The Lower Saxony Health Insurance Fund intends non-exclusive drug discount contracts for the active ingredient raltegravir (ATC code: J05AX08) with as many market participants as possible (pharmaceutical companies or communities pharmaceutical entrepreneur) in the so-called “open house model”.
The AOK Lower Saxony will not make a selection decision and will submit an identical contract offer to every interested pharmaceutical company. In the open house model, uniform conditions apply to all participants. Contract contents, terms and access procedures are uniform - individual negotiations are generally not conducted. The contract runs for a maximum of 24 months, the earliest contract start is October 1, 2020. All contracts end on 30.9.2022 at the latest, regardless of the date of the respective contract. An entry or a contract can be made within the 24 month period on the first of each month. There is a right of termination six weeks at the end of each month. AOK Niedersachsen reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts during the contract period. With the entry into force of exclusive discount contracts, the open house contracts are terminated in accordance with the contractual regulation, ie the open house contracts end automatically. According to the experience of the AOK Lower Saxony, exclusive discount contracts usually come into force six to eight months after the publication of the relevant announcement in the supplement to the Official Journal of the European Union. The future contractors in the open house model are asked to inform themselves regularly about these announcements in the supplement to the Official Journal of the European Union.
Interested pharmaceutical companies can request the contractual documents and the contractual terms and conditions at the contact address given under I.1).
Contracts for the active ingredient raltegravir will be concluded for the first time with effect from October 1, 2020. Interested parties who would like to become a contract partner on this date must submit the contract documents to be submitted by August 27, 2020 to the address specified in the contract documents. It depends on the access to the AOK Lower Saxony. Later contracts can be concluded on the first of a month during the 24-month maximum term. Organizationally, a lead time of generally 35 calendar days on the part of the AOK is necessary in order to carry out the required work, e.g. B. to be able to guarantee the contract registration in the Lauer-Taxe®. The exact entry deadlines will be announced with the contract documents. This publication is not a public contract within the meaning of Directive (2014/24 / EU) or the GWB. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are only due to the use of this notice form and the publication platform. This does not imply any further significance, in particular the submission of subcontracting regulations, unless they are legally binding.